Demand for Eli Lilly’s fast-acting insulin Humalog grew in the U.S. last year, but that didn’t stop sales from shrinking, driven by lower realized prices.
Levemir has long lived in the shadow of Sanofi’s megablockbuster Lantus, but it has chugged along, putting up blockbuster sales year after year for Novo Nordisk, with $2.54 billion last year worldwide, $1.82 billion of that in the U.S.
